Related Experiment Video
Updated: Oct 3, 2025
Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response
Published on: June 14, 2024
Therapeutic Targeting of DNA Damage Response in Cancer
Wonyoung Choi1,2, Eun Sook Lee1,3
1Research Institute, National Cancer Center, Goyang 10408, Korea.
Abstract:
DNA damage response (DDR) is critical to ensure genome stability, and defects in this signaling pathway are highly associated with carcinogenesis and tumor progression. Nevertheless, this also provides therapeutic opportunities, as cells with defective DDR signaling are directed to rely on compensatory survival pathways, and these vulnerabilities have been exploited for anticancer treatments. Following the impressive success of PARP inhibitors in the treatment of BRCA-mutated breast and ovarian cancers, extensive research has been conducted toward the development of pharmacologic inhibitors of the key components of the DDR signaling pathway. In this review, we discuss the key elements of the DDR pathway and how these molecular components may serve as anticancer treatment targets. We also summarize the recent promising developments in the field of DDR pathway inhibitors, focusing on novel agents beyond PARP inhibitors. Furthermore, we discuss biomarker studies to identify target patients expected to derive maximal clinical benefits as well as combination strategies with other classes of anticancer agents to synergize and optimize the clinical benefits.
Insights
Defects in DNA damage response (DDR) pathways are linked to cancer, offering therapeutic targets. This review explores novel DDR inhibitors beyond PARP inhibitors for enhanced cancer treatment strategies.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Genome stability is maintained by the DNA damage response (DDR) pathway.
- DDR pathway defects are strongly associated with cancer development and progression.
- Exploiting DDR vulnerabilities offers a promising avenue for anticancer therapies.
Purpose of the Study:
- To review key elements of the DDR pathway as potential anticancer targets.
- To summarize recent advancements in DDR pathway inhibitors, including novel agents.
- To discuss biomarkers for patient selection and combination strategies for optimized treatment.
Main Methods:
- Comprehensive literature review of the DNA damage response pathway.
- Analysis of pharmacologic inhibitors targeting key DDR components.
- Evaluation of biomarker studies and combination therapy approaches.
Main Results:
- DDR pathway components represent viable molecular targets for cancer therapy.
- Significant progress has been made in developing novel DDR inhibitors beyond PARP inhibitors.
- Biomarker-driven patient selection and combination strategies show potential for improved clinical outcomes.
Conclusions:
- Targeting the DDR pathway is a validated strategy in cancer treatment.
- Emerging DDR inhibitors offer new therapeutic options for various cancers.
- Personalized approaches integrating biomarkers and combination therapies are crucial for maximizing treatment efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:37DNA Damage can Stall the Cell Cycle
02:25Overview of DNA Repair
Chemically...
02:56Treatment Resistant Cancers
02:37DNA Damage Can Stall the Cell Cycle
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...